Abstract
Four cases of hepatic injury attributed to the use of pirprofen (Rengasil) were reported to the Monitoring
Centres for Adverse Reactions of Belgium, The Netherlands and the German Medical Association. One man
and three women developed severe hepatic injury between 31/2 and 61/2 months after starting treatment with
400-1200 mg pirprofen daily.
Histology showed acute hepatocellular damage, often with bridging necrosis. Two patients died. The other
two patients made an incomplete recovery. It is possible that this severe type of hepatic injury is due to a metabolic idiosyncrasy to pirprofen, as this reaction seems to be rare and unpredictable but is not associated with immunoallergic signs.
Centres for Adverse Reactions of Belgium, The Netherlands and the German Medical Association. One man
and three women developed severe hepatic injury between 31/2 and 61/2 months after starting treatment with
400-1200 mg pirprofen daily.
Histology showed acute hepatocellular damage, often with bridging necrosis. Two patients died. The other
two patients made an incomplete recovery. It is possible that this severe type of hepatic injury is due to a metabolic idiosyncrasy to pirprofen, as this reaction seems to be rare and unpredictable but is not associated with immunoallergic signs.
| Original language | English |
|---|---|
| Pages (from-to) | 127-132 |
| Journal | Journal of Hepatology |
| Volume | 4 |
| Publication status | Published - 1987 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Pirprofen-associated hepatic injury'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver